Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Warfarin for stroke prevention following anterior ST-elevation myocardial infarction.

Buss NI, Friedman SE, Andrus BW, DeVries JT.

Coron Artery Dis. 2013 Dec;24(8):636-41. doi: 10.1097/MCA.0000000000000032.

PMID:
23974463
2.

Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.

Schwalm JD, Ahmad M, Salehian O, Eikelboom JW, Natarajan MK.

J Thromb Thrombolysis. 2010 Aug;30(2):127-32. doi: 10.1007/s11239-010-0448-6.

PMID:
20157843
3.

Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.

Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W.

Ann Intern Med. 2013 Jun 18;158(12):861-8. doi: 10.7326/0003-4819-158-12-201306180-00003.

PMID:
23778903
4.

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.

Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB.

Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25.

PMID:
24016506
5.

Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients.

Karrowni W, Wang TY, Chen AY, Thomas L, Saucedo JF, El Accaoui RN.

Heart. 2015 Feb;101(4):264-70. doi: 10.1136/heartjnl-2014-305931. Epub 2014 Oct 21.

PMID:
25336230
6.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
7.

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.

Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators.

Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725. Epub 2015 Apr 7.

8.

Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.

Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, Lopes RD, Alexander KP, Wang TY.

Circulation. 2012 Mar 20;125(11):1414-23. doi: 10.1161/CIRCULATIONAHA.111.059188. Epub 2012 Feb 8.

9.

Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.

Homma S, Thompson JL, Sanford AR, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Massie BM, Labovitz AJ, Di Tullio MR, Gabriel AP, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators.

Circ Heart Fail. 2013 Sep 1;6(5):988-97. doi: 10.1161/CIRCHEARTFAILURE.113.000372. Epub 2013 Jul 23.

10.

Benefits and risks of anticoagulation resumption following traumatic brain injury.

Albrecht JS, Liu X, Baumgarten M, Langenberg P, Rattinger GB, Smith GS, Gambert SR, Gottlieb SS, Zuckerman IH.

JAMA Intern Med. 2014 Aug;174(8):1244-51. doi: 10.1001/jamainternmed.2014.2534.

11.

Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.

Hibbert B, MacDougall A, Labinaz M, O'Brien ER, So DY, Dick A, Glover C, Froeschl M, Marquis JF, Wells GA, Blondeau M, Le May MR.

Circ Cardiovasc Interv. 2012 Dec;5(6):805-12. doi: 10.1161/CIRCINTERVENTIONS.112.968966. Epub 2012 Nov 13.

12.

Prophylactic warfarin therapy after primary percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.

Le May MR, Acharya S, Wells GA, Burwash I, Chong AY, So DY, Glover CA, Froeschl MP, Hibbert B, Marquis JF, Dick A, Blondeau M, Bernick J, Labinaz M.

JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):155-62. doi: 10.1016/j.jcin.2014.07.018. Epub 2014 Oct 30.

13.

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin.

Saccullo G, Malato A, Raso S, Santoro M, Zammit V, Casuccio A, Siragusa S.

Am J Hematol. 2012 Apr;87(4):388-91. doi: 10.1002/ajh.23122. Epub 2012 Feb 28.

14.

Warfarin and aspirin in patients with heart failure and sinus rhythm.

Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators.

N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2.

15.

Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin.

Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, Lip GY.

Am J Med. 2014 Apr;127(4):329-336.e4. doi: 10.1016/j.amjmed.2013.12.005. Epub 2013 Dec 19.

PMID:
24361757
16.

Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.

Yusuf S, Mehta SR, Xie C, Ahmed RJ, Xavier D, Pais P, Zhu J, Liu L; CREATE Trial Group Investigators.

JAMA. 2005 Jan 26;293(4):427-35.

PMID:
15671427
17.

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P; Warfarin-Aspirin Recurrent Stroke Study Group.

N Engl J Med. 2001 Nov 15;345(20):1444-51.

18.

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.

Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2662-8. doi: 10.2215/CJN.04550511. Epub 2011 Sep 29.

19.

Anticoagulation after anterior myocardial infarction and the risk of stroke.

Udell JA, Wang JT, Gladstone DJ, Tu JV.

PLoS One. 2010 Aug 13;5(8):e12150. doi: 10.1371/journal.pone.0012150.

20.

Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up study.

Palnum KH, Mehnert F, Andersen G, Ingeman A, Krog BR, Bartels PD, Johnsen SP.

Stroke. 2012 Mar;43(3):802-7. doi: 10.1161/STROKEAHA.111.635342. Epub 2011 Dec 29.

Items per page

Supplemental Content

Write to the Help Desk